Skip to search formSkip to main contentSkip to account menu

Caspofungin

Known as: (4R,5S)-5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(P-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide, (4R,5S)-5-((2-aminoethyl)amino)-n2-(10,12-dimethyltetradecanoyl)-4-hydroxy-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-threo-3-hydroxy-l-ornithyl-trans-3-hydroxy-l-proline cyclic (1->6) disulfide, 1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin b0 
The acetate salt of an antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis… 
National Institutes of Health

Related topics

Related topics

19 relations

Broader (3)

Antifungal AgentsEchinocandinsLipopeptides
AspergillosisCaspofungin acetate 50 MG InjectionCaspofungin acetate 70 MG Injection [Cancidas]Caspofungin:MCnc:Pt:Ser/Plas:Qn

Narrower (4)

CancidasCaspofungin acetateL 743,872MK 0991

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility.
2015
2015
Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Review
2010
Review
2010
Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital.
Mucormycosis is an angio-invasive mycosis with high morbidity and mortality rates which mainly affects immunocompromised patients… 
Highly Cited
2009
Highly Cited
2009
Phaeohyphomycosis due to Alternaria species in transplant recipients
R.D. Boyce, P.J. Deziel, C.C. Otley, M.P. Wilhelm, A.J. Eid, N.L. Wengenack, R.R. Razonable. Phaeohyphomycosis due to Alternaria… 
Highly Cited
2007
Highly Cited
2007
A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK
Objective:  To evaluate the cost‐effectiveness of caspofungin vs. liposomal amphotericin B in the treatment of suspected fungal… 
Highly Cited
2006
Highly Cited
2006
Characterizing the Effects of Caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata Isolates by Simultaneous Time-Kill and Postantifungal-Effect Experiments
ABSTRACT We measured time-kills and postantifungal effects (PAFEs) of caspofungin against Candida albicans, C. parapsilosis, and… 
Highly Cited
2005
Highly Cited
2005
Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies
Invasive Fungal Infections (IFI) remain a severe and major complication among patients with hematologic diseases, but the recent… 
Highly Cited
2005
Highly Cited
2005
Comparison of Two Probes for Testing Susceptibilities of Pathogenic Yeasts to Voriconazole, Itraconazole, and Caspofungin by Flow Cytometry
ABSTRACT A cytometric approach to determine the susceptibilities of Candida spp. and Cryptococcus neoformans to voriconazole… 
2004
2004
Refractory Candidal Meningitis in an Immunocompromised Patient Cured by Caspofungin
ABSTRACT Candidal meningitis is a rare infectious disease that usually leads to substantial morbidity and mortality. We present a… 
Highly Cited
2004
Highly Cited
2004
Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis
Abstract:  Objective: Data on the use of combination of liposomal amphotericin B and caspofungin followed by voriconazole, as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)